Gina Tourassi has been appointed as director of the National Center for Computational Sciences, a division of the Computing and Computational Sciences Directorate at Oak Ridge National Laboratory.
Kathy McCarthy has been named director of the US ITER Project Office at the Department of Energy’s Oak Ridge National Laboratory, effective March 2020.
Researchers at the Department of Energy’s Oak Ridge National Laboratory have received five 2019 R&D 100 Awards, increasing the lab’s total to 221 since the award’s inception in 1963.
The U.S. Department of Energy announced funding for 12 projects with private industry to enable collaboration with DOE national laboratories on overcoming challenges in fusion energy development.
ORNL and The University of Toledo have entered into a memorandum of understanding for collaborative research.
Craig Blue, a program director at the Department of Energy’s Oak Ridge National Laboratory, has been elected a 2019 fellow for SME (formerly known as the Society for Manufacturing Engineers).
An ORNL-led team's observation of certain crystalline ice phases challenges accepted theories about super-cooled water and non-crystalline ice. Their findings, reported in the journal Nature, will also lead to better understanding of ice and its various phases found on other planets, moons and elsewhere in space.
OAK RIDGE, Tenn., May 8, 2019—Oak Ridge National Laboratory and Lincoln Electric (NASDAQ: LECO) announced their continued collaboration on large-scale, robotic additive manufacturing technology at the Department of Energy’s Advanced Manufacturing InnovationXLab Summit.
OAK RIDGE, Tenn., May 7, 2019—The U.S. Department of Energy today announced a contract with Cray Inc. to build the Frontier supercomputer at Oak Ridge National Laboratory, which is anticipated to debut in 2021 as the world’s most powerful computer with a performance of greater than 1.5 exaflops.
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.